[1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V. et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380(9859), 2095-2128. DOI: 10.1016/S0140-6736(12)61728-0.10.1016/S0140-6736(12)61728-0]Search in Google Scholar
[2. Mathers CD, Loncar D. (2006). Projections of Global Mortality and Burden of Disease from 2002 to 2030. Plos Medicine. 3(11), 2011-2030. DOI:10.1371/journal. pmed.003044210.1371/journal.pmed.0030442]Search in Google Scholar
[3. Blasi F, Cesana G, Conti S, Chiodini V, Aliberti S, Fornari C & Mantovani LG. (2014). The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 9(6), 1-8. DOI:10.1371/journal.pone.010122810.1371/journal.pone.0101228407419024971791]Search in Google Scholar
[4. Wan E, DeMeo D, Hersh C, Shapiro S, Rosiello R, Sama S, Fuhlbrigge A, Foreman M & Silverman E. (2011). Clinical predictors of frequent exacerbations in subjects with 6 severe chronic obstructive pulmonary disease (COPD). Respir Med. 105(4), 588–594. DOI: 10.1016/j.rmed.2010.11.01510.1016/j.rmed.2010.11.015304631221145719]Search in Google Scholar
[5. Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF & Wedzicha JA. (2010). Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 363(12), 1128-1138. DOI:10.1056/NEJMoa0909883.10.1056/NEJMoa090988320843247]Search in Google Scholar
[6. Parikh R, Shah TG & Tandon R. (2016). COPD exacerbation care bundle improves standard of care, length of stay, and readmission rates. Int J Chron Obstruct Pulmon Dis. 11(1), 577-583. DOI: 10.2147/COPD.S100401.10.2147/COPD.S100401480115927042046]Search in Google Scholar
[7. Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F & Galvn L. (2015). Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study. BMC Fam Pract. 16:173. DOI: 10.1186/s12875-015-0387-610.1186/s12875-015-0387-6467252826642879]Search in Google Scholar
[8. Guarascio AJ, Ray SM, Finch CK & Self TH. (2013). The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 5, 235-245. DOI: 10.2147/CEOR.S3432110.2147/CEOR.S34321369480023818799]Search in Google Scholar
[9. Lazic Z, Gajovic O, Tanaskovic I, Milovanovic D, Atanasijevic D & Jakovljevic M. (2012). GOLD Stage Impact on COPD Direct Medical Costs in the Elderly. Health Behav & Pub Health. 2(3), 1-7.]Search in Google Scholar
[10. Menn P, Leidl R & Holle R. (2012). A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 30(9), 825-840. DOI: 10.2165/11591340-000000000-0000010.2165/11591340-000000000-0000022799876]Search in Google Scholar
[11. Hoogendoorn M, Kappelhoff BS, Overbeek JA, Wouters EF & Rutten-van Mölken MP. (2012). Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Neth J Med. Review. 70(8), 357-364.]Search in Google Scholar
[12. Ornek T, Tor M, Altın R, Atalay F, Geredeli E, Soylu O & Erboy F. (2012). Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int J Med Sci. 9(4), 285-90. DOI: 10.7150/ijms.403910.7150/ijms.4039337293422701335]Search in Google Scholar
[13. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M & Blum S. (2011). Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 14(3), 315-323. DOI: 10.3111/13696998.2011.576295.10.3111/13696998.2011.57629521500975]Search in Google Scholar
[14. Abudagga A, Sun SX, Tan H & Solem CT. (2013). Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis. 8, 175-85. DOI: 10.2147/COPD.S40437.10.2147/COPD.S40437362496523589684]Search in Google Scholar
[15. Global Initiative for Chronic Obstructive Lung Disease. (2014). Global Strategy for the Diagnosis. Management and Prevention of Chronic Obstructive Pulmonary Disease. Available on: http://www.goldcopd.org]Search in Google Scholar
[16. World Health Organization. Chronic obstructive pulmonary disease (COPD).(2011). Available on: http://www.who.int/respiratory/copd/en/]Search in Google Scholar
[17. Valente S, Pasciuto G, Bernabei R & Corbo GM. (2010). Do we need different treatments for very elderly COPD patients? Respiration. 80(5), 357–368. DOI: 10.1159/000320221.10.1159/00032022120733280]Search in Google Scholar
[18. Hillas G, Perlikos F, Tsiligianni I & Tzanakis N. (2015). Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 10, 95-109. DOI: 10.2147/COPD. S54473.10.2147/COPD]Search in Google Scholar
[19. Pasquale MK, Sun SX, Song F, Hartnett HJ & Stem-kowski SA. (2012). Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 7, 757-764. DOI: 10.2147/COPD.S36997.10.2147/COPD.S36997349653623152680]Search in Google Scholar
[20. Doos L, Uttley J, Onyia I, Iqbal Z, Jones PW & Kadam UT. (2014). Mosaic segmentation, COPD and CHF multimorbidity and hospital admission costs: a clinical linkage study. J Public Health (Oxf). 36(2), 317-324. DOI: 10.1093/pubmed/fdt070.10.1093/pubmed/fdt07023903003]Search in Google Scholar
[21. Halpin DM & Miravitlles M. (2006). Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 3(7), 619–623. DOI: 10.1513/pats.200603-093SS10.1513/pats.200603-093SS16963544]Search in Google Scholar
[22. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA & Coultas DB. (2000). Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med. 160(17), 2653–2658. DOI:10.1001/archinte.160.17.265310.1001/archinte.160.17.265310999980]Search in Google Scholar
[23. Cazzola M, Bettoncelli G, Sessa E, Cricelli C & Biscione G. (2010). Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 80(2), 112–119. DOI: 10.1159/00028188010.1159/00028188020134148]Search in Google Scholar
[24. Mannino DM1, Watt G, Hole D, Gillis C, Hart C, Mc-Connachie A, Davey Smith G, Upton M, Hawthorne V, Sin DD, Man SF, Van Eeden S, Mapel DW & Vestbo J. (2006). The natural history of chronic obstructive pulmonary disease. Eur Respir J. 27(3), 627–643. DOI: 10.1183/09031936.06.0002460510.1183/09031936.06.0002460516507865]Search in Google Scholar
[25. Säynäjäkangas O, Kinnunen T, Tuuponen T & Keistinen T. (2004). Length of stay and interval to readmission in emergency hospital treatment of COPD. Age Ageing. 33(6), 567-570. DOI: 10.1093/ageing/afh18810.1093/ageing/afh18815347536]Search in Google Scholar
[26. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A & White PT. (2015). Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. Int J Chron Obstruct Pulmon Dis. 10, 603-611. DOI: 10.2147/COPD. S77092.10.2147/COPD]Search in Google Scholar
[27. Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A & Papaioannou A. (2014). Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score. Respir Care. 59(11), 1679-1686. DOI: 10.4187/respcare.03171.10.4187/respcare.0317124962226]Search in Google Scholar
[28. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S & Jameson K. (2012). Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 7, 183-199. DOI: 10.2147/COPD.S29820.10.2147/COPD.S29820332500022500119]Search in Google Scholar